Oral vancomycin prophylaxis for the prevention of Clostridium difficile infection: A systematic review and meta-analysis

被引:17
|
作者
Babar, Sumbal [1 ]
El Kurdi, Bara [1 ]
El Iskandarani, Mahmoud [1 ]
Haddad, Ibrahim [1 ]
Imam, Zaid [3 ]
Alomari, Mohammad [2 ]
Myers, James [1 ,4 ]
Moorman, Jonathan [4 ]
机构
[1] East Tennessee State Univ, Dept Internal Med, Johnson City, TN 37614 USA
[2] Cleveland Clin Fdn, Dept Internal Med, 9500 Euclid Ave, Cleveland, OH 44195 USA
[3] William Beaumont Hosp, Dept Internal Med, Royal Oak, MI 48073 USA
[4] East Tennessee State Univ, Div Infect Dis, Johnson City, TN USA
来源
关键词
EFFICACY; EPIDEMIC; COLITIS;
D O I
10.1017/ice.2020.277
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective: Recently, oral vancomycin prophylaxis (OVP) has been suggested for the prevention of Clostridium difficile infection (CDI). We conducted a systematic review and meta-analysis to investigate the efficacy and safety of this approach. Design: Systematic review and meta-analysis. Methods: We conducted a computerized search of MEDLINE, EMBASE, and Cochrane databases from inception to March 2019 for publications investigating OVP for CDI prevention. Results were screened for eligibility. Relevant data were extracted and analyzed. Publication bias was assessed using the Egger test. Results: Ultimately, 8 retrospective studies and 1 prospective study examining 2174 patients, published between 2016 and 2019 were included in the review. OVP was associated with decreased CDI (odds ratio, 0.263; 95% confidence interval, 0.13-0.52) with considerable heterogeneity (I-2 = 61%). Meta-regression showed that total daily dose of OVP correlated with CDI, explaining 100% of heterogeneity between studies. Furthermore, 3 studies evaluated the risk of vancomycin-resistant enterococci (VRE) infection after OVP and found no significant increase. Conclusion: Our results suggest that OVP might decrease CDI rates in at-risk populations, although this conclusion should be interpreted with caution. Higher daily doses of OVP might increase CDI. Although the use of OVP in high-risk patients may reduce CDI, this suggestion has yet to be validated by prospective blinded randomized controlled trials.
引用
收藏
页码:1302 / 1309
页数:8
相关论文
共 50 条
  • [1] Oral Vancomycin Prophylaxis for the Primary and Secondary Prevention of Clostridium difficile Infection: A Systematic Review and Meta-Analysis
    El Kurdi, Bara
    El Iskandarani, Mahmoud
    Babar, Sumbal
    Haddad, Ibrahim
    Alomari, Mohammad
    Al Momani, Laith
    Young, Mark
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S126 - S126
  • [2] Efficacy of oral vancomycin prophylaxis for prevention of Clostridioides difficile infection: a systematic review and meta-analysis
    Tariq, Raseen
    Laguio-Vila, Maryrose
    Tahir, Muhammad Waqas
    Orenstein, Robert
    Pardi, Darrell S.
    Khanna, Sahil
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
  • [3] EFFICACY OF ORAL VANCOMYCIN PROPHYLAXIS FOR PREVENTION OF CLOSTRIDIOIDES DIFFICILE INFECTION: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Tariq, Raseen
    LaguioVila, Maryrose
    Kamal, Faisal
    Hayat, Maham
    Orenstein, Robert
    Pardi, Darrell S.
    Khanna, Sahil
    [J]. GASTROENTEROLOGY, 2019, 156 (06) : S897 - S898
  • [4] Oral Vancomycin for Secondary Prophylaxis of Clostridium difficile Infection
    Brown, Chase C.
    Manis, Melanie M.
    Bohm, Nicole M.
    Curry, Scott R.
    [J]. ANNALS OF PHARMACOTHERAPY, 2019, 53 (04) : 396 - 401
  • [5] Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review
    Al Momani, Laith A.
    Abughanimeh, Omar
    Boonpheng, Boonphiphop
    Gabriel, Joseph Gabriel
    Young, Mark
    [J]. CUREUS, 2018, 10 (06):
  • [6] Efficacy of fidaxomicin versus vancomycin in the treatment of Clostridium difficile infection: A systematic meta-analysis
    Zhao, Zihan
    Wu, Yarui
    Geng, Xuhua
    Yuan, Congrui
    Fu, Yi
    Yang, Guibin
    [J]. MEDICINE, 2024, 103 (32)
  • [7] Oral Vancomycin Prophylaxis for Primary and Secondary Prevention of Clostridioides difficile Infection in Patients Treated with Systemic Antibiotic Therapy: A Systematic Review, Meta-Analysis and Trial Sequential Analysis
    Maraolo, Alberto Enrico
    Mazzitelli, Maria
    Zappulo, Emanuela
    Scotto, Riccardo
    Granata, Guido
    Andini, Roberto
    Durante-Mangoni, Emanuele
    Petrosillo, Nicola
    Gentile, Ivan
    [J]. ANTIBIOTICS-BASEL, 2022, 11 (02):
  • [8] SUROTOMYCIN (A NOVEL ANTIBIOTIC) VS VANCOMYCIN FOR CLOSTRIDIUM DIFFICILE INFECTION: A SYSTEMATIC REVIEW AND META ANALYSIS
    Aziz, Muhammad
    Chandrasekar, Viveksandeep Thogulva
    Desai, Madhav
    Fatima, Rawish
    Jackson, Mollie
    Sharma, Prateek
    [J]. GASTROENTEROLOGY, 2018, 154 (06) : S421 - S421
  • [9] Prolonged oral vancomycin for secondary prophylaxis of relapsing Clostridium difficile infection
    Zhang, Kevin
    Beckett, Patricia
    Abouanaser, Salaheddin
    Stankus, Vida
    Lee, Christine
    Smieja, Marek
    [J]. BMC INFECTIOUS DISEASES, 2019, 19 (1)
  • [10] Prolonged oral vancomycin for secondary prophylaxis of relapsing Clostridium difficile infection
    Kevin Zhang
    Patricia Beckett
    Salaheddin Abouanaser
    Vida Stankus
    Christine Lee
    Marek Smieja
    [J]. BMC Infectious Diseases, 19